Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 5/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL556606 | 0.88 | MTNR1A (0.44) | MTNR1AMTNR1BSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL533826 | 0.78 | MTNR1A (0.49) | MTNR1AMTNR1B | |
| SCHEMBL533923 | 0.78 | MTNR1A (0.48) | MTNR1AMTNR1BSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL534744 | 0.75 | MTNR1A (0.51) | MTNR1AMTNR1BLMNABLM | |
| SCHEMBL557108 | 0.65 | MTNR1A (0.36) | MTNR1AMTNR1BKDM4EALDH1A1LMNA | |
| SCHEMBL533955 | 0.65 | MTNR1A (0.51) | MTNR1AMTNR1BLMNABLM | |
| SCHEMBL2930875 | 0.65 | TTR (0.41) | KDM4EALDH1A1MAPTHPGDHSD17B10 | |
| SCHEMBL534402 | 0.64 | MTNR1A (0.52) | MTNR1AMTNR1B | |
| SCHEMBL556901 | 0.64 | TAAR1 (0.40) | MTNR1AMTNR1BSMN1; SMN2MAPTHPGD | |
| SCHEMBL555531 | 0.63 | SMN1; SMN2 (0.50) | SMN1; SMN2LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2012-02-09 | — | — | US | disclosed |
| EP-2413941-A1 | RENIN INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-02-08 | — | — | EP | disclosed |
| WO-2010114978-A1 | RENIN INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | MTNR1A 2293/4885MTNR1B 1285/4885SMN1; SMN2 4604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.